日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome

恶性疟原虫蛋白酶体新型硼酸盐抑制剂的靶标验证与鉴定

Stanley C Xie, David L Gillett, Natalie J Spillman, Christopher Tsu, Madeline R Luth, Sabine Ottilie, Sandra Duffy, Alexandra E Gould, Paul Hales, Benjamin A Seager, Carlie L Charron, Frank Bruzzese, Xiaofeng Yang, Xiansi Zhao, Shih-Chung Huang, Craig A Hutton, Jeremy N Burrows, Elizabeth A Winzeler

Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity

需要同时抑制免疫蛋白酶体亚基 LMP2 和 LMP7 才能阻断自身免疫

Michael Basler, Michelle M Lindstrom, Jacob J LaStant, J Michael Bradshaw, Timothy D Owens, Christian Schmidt, Elmer Maurits, Christopher Tsu, Herman S Overkleeft, Christopher J Kirk, Claire L Langrish, Marcus Groettrup

Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi

用于治疗多发性骨髓瘤的蛋白酶体抑制剂硼替佐米和卡非佐米不抑制丝氨酸蛋白酶 HtrA2/Omi

Vilmos Csizmadia, Paul Hales, Christopher Tsu, Jingya Ma, Jiejin Chen, Pooja Shah, Paul Fleming, Joseph J Senn, Vivek J Kadambi, Larry Dick, Francis S Wolenski

Cleavage Specificity of Mycobacterium tuberculosis ClpP1P2 Protease and Identification of Novel Peptide Substrates and Boronate Inhibitors with Anti-bacterial Activity

结核分枝杆菌ClpP1P2蛋白酶的切割特异性及具有抗菌活性的新型肽底物和硼酸酯抑制剂的鉴定

Tatos Akopian, Olga Kandror, Christopher Tsu, Jack H Lai, Wengen Wu, Yuxin Liu, Peng Zhao, Annie Park, Lisa Wolf, Lawrence R Dick, Eric J Rubin, William Bachovchin, Alfred L Goldberg

Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea

硼替佐米与维生素 C 或表没食子儿茶素没食子酸酯(绿茶成分)联合使用的抗肿瘤活性的临床前评估

Bret Bannerman, Ling Xu, Matthew Jones, Christopher Tsu, Jie Yu, Paul Hales, Johan Monbaliu, Paul Fleming, Lawrence Dick, Mark Manfredi, Christopher Claiborne, Joseph Bolen, Erik Kupperman, Allison Berger

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer

蛋白酶体抑制剂 MLN9708 在人类癌症临床前模型中的评估

Erik Kupperman, Edmund C Lee, Yueying Cao, Bret Bannerman, Michael Fitzgerald, Allison Berger, Jie Yu, Yu Yang, Paul Hales, Frank Bruzzese, Jane Liu, Jonathan Blank, Khristofer Garcia, Christopher Tsu, Larry Dick, Paul Fleming, Li Yu, Mark Manfredi, Mark Rolfe, Joe Bolen